MarketCapExport financials
Phreesia (PHR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Phreesia Cash Flow 2026-2011 | PHR
Brief overview of Phreesia's cash movements
Cash flow changes are traced through the five latest available reports from 2022 to 2026.
Operating cash flow reversed from -$74.7 million to $78.8 million, improving the company's ability to fund itself.
Operating cash flow was positive in only 2 of five periods. Cash generation remains unstable.
At the end, 16.4% of revenue converted into operating cash flow versus -35% previously.
What the cash flows show
Phreesia's cash flow is not clear-cut. Operating receipts exist, but their stability or the residual after investment needs attention.
Annual Cash Flow Phreesia
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
78.8 M | 32.4 M | -32.4 M | -90.1 M | -74.7 M | 2.89 M | 826 K | -2.13 M | -11.1 M | - | - | - | - | - | - | - |
Depreciation & Amortization |
31.5 M | 27.9 M | 29.5 M | 25.3 M | 21.3 M | 15.9 M | 13.9 M | 11.6 M | 9.64 M | - | - | - | - | - | - | - |
Accounts Payables |
11.5 M | 5.62 M | 8.48 M | 10.8 M | 5.12 M | 4.39 M | 6.02 M | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
97.5 M | 73.6 M | 64.9 M | 51.4 M | 40.3 M | 29.1 M | 22 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Phreesia
| 2027-Q2 | 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
14.8 M | 23.9 M | - | 15.5 M | 14.8 M | 14.8 M | - | 5.78 M | 14.8 M | 14.8 M | - | 5.78 M | 11.1 M | -721 K | - | -6.31 M | - | -13.7 M | - | -74.2 M | -53.5 M | -33.6 M | - | -36.7 M | -12.2 M | -5.47 M | - | -1.19 M | -520 K | 1.9 M | - | -448 K | 2.58 M | 2.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
871 K | 9.95 M | - | 7.48 M | 7.41 M | 6.88 M | - | 7.09 M | 7.41 M | 6.88 M | - | 7.09 M | 7.3 M | 6.67 M | - | 7.46 M | 4.24 M | 6.99 M | - | 4.86 M | 4.22 M | 5.88 M | - | 15.5 M | 10.2 M | 4.95 M | - | 11.7 M | 7.66 M | 3.62 M | - | 10.3 M | 6.79 M | 3.37 M | - | 1.97 M | 1.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
11.5 M | 11.9 M | 5.62 M | 6.22 M | 6.53 M | 3.2 M | 8.48 M | 15.9 M | 6.53 M | 3.2 M | 10.8 M | 15.9 M | - | 6.68 M | 5.12 M | 10.9 M | 7.95 M | 7.6 M | 10.8 M | 11.1 M | 10.1 M | 5.87 M | 4.39 M | 11.6 M | 5.48 M | 313 K | 6.02 M | 4.22 M | 5.1 M | 7.65 M | 3.75 M | 5.95 M | 11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
840 K | 89.6 M | - | 88.3 M | 76.8 M | 75.1 M | 64.9 M | 71.4 M | 76.8 M | 75.1 M | 51.4 M | 71.4 M | - | 66.3 M | 40.3 M | 57.4 M | 53.9 M | 52.9 M | 51.4 M | 44.4 M | 47 M | 46.4 M | 29.1 M | 35.5 M | 30.4 M | 30 M | 22 M | 27.6 M | 23 M | 24.2 M | 16.1 M | 20 M | 16.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Phreesia, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Health information services sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Zhongchao
ZCMD
|
$ 1.2 | -6.98 % | $ 4.1 M |  China |
 |
So-Young International
SY
|
$ 2.13 | 0.71 % | $ 166 M | China |
 |
Evolent Health
EVH
|
$ 4.39 | -6.98 % | $ 501 M |  USA |
 |
Progyny
PGNY
|
$ 28.34 | -2.17 % | $ 2.42 B | USA |
 |
10x Genomics
TXG
|
$ 73.51 | 2.74 % | $ 9.17 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
$ 7.25 | 31.34 % | $ 52.7 M | USA |
 |
American Well Corporation
AMWL
|
$ 13.44 | -0.92 % | $ 216 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Health Catalyst
HCAT
|
$ 1.65 | -2.66 % | $ 115 M | USA |
 |
HealthStream
HSTM
|
$ 34.57 | -1.65 % | $ 1.04 B | USA |
 |
Omnicell
OMCL
|
$ 37.37 | -1.01 % | $ 1.72 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 8.98 | -1.91 % | $ 167 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.52 | -0.56 % | $ 1.25 B | USA |
 |
HealthEquity
HQY
|
$ 103.34 | -0.61 % | $ 8.9 B | USA |
 |
Schrödinger
SDGR
|
$ 24.58 | 3.28 % | $ 1.81 B | USA |
 |
Teladoc Health
TDOC
|
$ 6.18 | -2.6 % | $ 1.09 B | USA |
 |
Veeva Systems
VEEV
|
$ 318.06 | -1.51 % | $ 52.1 B | USA |